Fosfomycin I.v. for Treatment of Severely Infected Patients

Inclusion Criteria:

• Male or female patients aged ≥ 18 years

• Treatment with fosfomycin according to the (national) Summary of ProductCharacteristics (SmPC) of fosfomycin i.v.

• Patients with osteomyelitis, complicated urinary tract infection, nosocomial lowerrespiratory tract infection, bacterial meningitis/central nervous system infection,bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection,each as far as covered by the respective nationally relevant SmPC

• Written informed consent of the participant (or person in charge in case of patientsincapable of giving consent)

Exclusion Criteria:

• Previous documentation of the patient in the present study

• Patients participating in an interventional clinical trial

• Patients with known hypersensitivity to fosfomycin or any of the excipients

• Terminally ill patients

• Patients with "do not resuscitate order"

• Palliative treatment approach

• Failure of > 3 of the following organ systems: respiratory system, nervous system,cardiovascular system, liver, coagulation, kidney

• Manifest Human Immunodeficiency Virus (HIV) disease (Acquired ImmunodeficiencySyndrome, AIDS)

• Fosfomycin treatment as 4th line treatment or at later stage

• Patients with involvement of fungi or mycobacteria in the targeted infection